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Xiaoyi Zhang, J. Madison Hyer, Hong Yu,
Nisha J. D’Silva, and Keith L. Kirkwood
Precis: Results from studies of oral cancer offer the first
definitive establishment of Dusp1 as a tumor suppressor
gene that regulates cancer-associated inflammation.
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Denise Schultz, Natalia Scaglia, Jonathan McDunn,
Angelo M. De Marzo, and Massimo Loda
Precis: These findings may pave the way for a metabolic
classification of prostate tumors that is complementary to
genomics and signaling pathway analyses, with
implications for the development of metabolic diagnostics
and targeted therapeutics.
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Sangkon Oh, Marshall R. Posner, and
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Precis: Findings from a small clinical study strongly
encourage human trials of PD-1–blocking antibodies in
combination with standard-of-care therapy for HPV-
associated oral cancers, the incidence of which has been
rising rapidly.
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7217 Adaptive Responses to Dasatinib-Treated Lung
Squamous Cell Cancer Cells Harboring DDR2
Mutations
Yun Bai, Jae-Young Kim, January M. Watters,
Bin Fang, Fumi Kinose, Lanxi Song, JohnM. Koomen,
Jamie K. Teer, Kate Fisher, Yian Ann Chen, Uwe Rix,
and Eric B. Haura
Precis: This study of cancer cell signaling perturbed by the
tyrosine kinase inhibitor dasatinib suggests rational
combinations to improve the efficacy of this drug in the
subset of lung cancers where it is used.
7229 Bioengineered Implantable Scaffolds as a Tool
to Study Stromal-Derived Factors in Metastatic
Cancer Models
Francesca Bersani, Jungwoo Lee, Min Yu,
Robert Morris, Rushil Desai, Sridhar Ramaswamy,
Mehmet Toner, Daniel A. Haber, and
Biju Parekkadan
Precis: This study describes a bioengineered platform that
allows detailed cellular and molecular characterization of
the metastatic microenvironment in vivo, providing a new
tool for a better understanding of tumor/stromal
interactions at secondary sites.
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MICROENVIRONMENT AND IMMUNOLOGY
7239 Adenosine A2A Receptors Intrinsically
Regulate CD8þ T Cells in the Tumor
Microenvironment
Caglar Cekic and Joel Linden
Precis: Targeted deletion of the adenosine A2A receptor, an
important inhibitory receptor on T cells, paradoxically
enhances the growth rate of solid tumors by impairing
tumor-associated T-cell maintenance and effector/memory
differentiation, with implications for clinical testing of A2A
receptor antagonists to enhance cancer immunotherapy.
7250 Myeloid Expression of Adenosine A2A Receptor
Suppresses T and NK Cell Responses in the
Solid Tumor Microenvironment
Caglar Cekic, Yuan-Ji Day, Duygu Sag, and
Joel Linden
Precis: This study provides a mechanistic rationale to
reposition inhibitors of a certain class of cell surface
adenosine receptors to block an important pathway of
immune escape that is commonly activated in solid tumors,
with immediate implications for clinical evaluation.
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Franz J. Zemp, Brienne A. McKenzie, Xueqing Lun,
Karlyne M. Reilly, Grant McFadden, V. Wee Yong,
and Peter A. Forsyth
Precis: This study identifies specific leukocyte classes that
are responsible for conferring resistance to oncolytic viral
therapy in a syngeneic orthotopic model of glioma,
demonstrating the importance of immunocompetency in
preclinical models of this type of therapy and suggesting
immune-based strategies to improve its efficacy.
7274 Myeloid IKKb Promotes Antitumor Immunity
by Modulating CCL11 and the Innate Immune
Response
Jinming Yang, Oriana E. Hawkins,
Whitney Barham, Pavlo Gilchuk, Mark Boothby,
Gregory D. Ayers, Sebastian Joyce, Michael Karin,
Fiona E. Yull, and Ann Richmond
Precis: The importance of maintaining NF-kB in myeloid
cells to optimize the host antitumor response is illustrated
in melanoma tumor models, illuminating mechanisms
relevant to therapeutics affecting this pathway.
7285 RAGE Expression in Tumor-Associated
Macrophages Promotes Angiogenesis in
Glioma
Xuebo Chen, Leying Zhang, Ian Y. Zhang,
Junling Liang, Huaqing Wang, Mao Ouyang,
Shihua Wu, Anna Carolina Carvalho da Fonseca,
Lihong Weng, Yasuhiko Yamamoto,
Hiroshi Yamamoto, Rama Natarajan, and
Behnam Badie
Precis: Signaling by a proinflammatory receptor in
glioma-associated microglial and macrophages drives
angiogenesis in the tumor microenvironment, reinforcing
interest in this receptor as a therapeutic target in glioma.
7298 Natural Killer Cells Are Essential for the
Ability of BRAF Inhibitors to Control
BRAFV600E-Mutant Metastatic Melanoma
Lucas Ferrari de Andrade, Shin F. Ngiow,
Kimberley Stannard, Sylvie Rusakiewicz,
Murugan Kalimutho, Kum Kum Khanna,
Siok-Keen Tey, Kazuyoshi Takeda,
Laurence Zitvogel, Ludovic Martinet, and
Mark J. Smyth
Precis: This seminal study shows that, like imatinib,
inhibitors of mutant BRAF must engage the immune
system to elicit their profound antitumor effects, offering
further encouragement to the concept that
immunotherapeutic responses form the foundation of any
effective cancer therapy.
7309 ISG15 Is a Critical Microenvironmental Factor
for Pancreatic Cancer Stem Cells
Bruno Sainz Jr, Beatriz Martı´n, Marianthi Tatari,
Christopher Heeschen, and Susana Guerra
Precis: This study highlights the role of a previously
unrecognized support factor in the tumor
microenvironment for cancer stem cells in pancreatic
cancer, with implications for tractable new strategies to
attack this deadly disease.
MOLECULAR AND CELLULAR
PATHOBIOLOGY
7321 Astrocyte Elevated Gene-1 Interacts with Akt
Isoform 2 to Control Glioma Growth, Survival,
and Pathogenesis
Bin Hu, Luni Emdad, Manny D. Bacolod,
Timothy P. Kegelman, Xue-Ning Shen,
Mohammad A. Alzubi, Swadesh K. Das,
Devanand Sarkar, and Paul B. Fisher
Precis: These results illuminate a central mechanism of
glioma progression and provide a rationale to target this
mechanism as a novel treatment in this setting.
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Pathway to Suppress Lung Cancer Metastasis
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Kuan-Hsien Chou, Wen-Feng Huang,
Wan-Ping Wang, Yih-Leh Huang, Chiun Hsu,
Liang-In Lin, Yueh-Min Lin, C.-K. James Shen, and
Tsai-Yu Tzeng
Precis: These findings provide important mechanistic
insights into how TGFb promotes lung cancer metastasis,
with possible implications for understanding how to target
this broadly important pathway in cancer progression.
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Muscle Wasting in Cancer
Yann S. Gallot, Anne-Cecile Durieux,
Josiane Castells, Marine M. Desgeorges,
Barbara Vernus, Lea Plantureux, Didier Remond,
Vanessa E. Jahnke, Etienne Lefai,
Dominique Dardevet, Georges Nemoz,
Laurent Schaeffer, Anne Bonnieu, and
Damien G. Freyssenet
Precis: Striking preclinical results suggest that targeting a
TGFb-related protein that inhibits muscle differentiation
may not only impede muscle wasting (cachexia) in
patients with advanced cancer, but also limit malignant
growth and increase survival.
7357 Homeoprotein Six2 Promotes Breast Cancer
Metastasis via Transcriptional and Epigenetic
Control of E-Cadherin Expression
Chu-An Wang, David Drasin, Catherine Pham,
Paul Jedlicka, Vadym Zaberezhnyy,
Michelle Guney, Howard Li, Raphael Nemenoff,
James C. Costello, Aik-Choon Tan, and
Heide L. Ford
Precis: A transcription factor that regulates normal
kidney development is found to be switched on in
aggressive breast cancers, where it drives metastasis in
part by downregulating E-cadherin.
7371 Mig-6 Suppresses Endometrial Cancer
Associated with Pten Deficiency and ERK
Activation
Tae Hoon Kim, Jung-Yoon Yoo, Hong Im Kim,
Jenifer Gilbert, Bon Jeong Ku, Jane Li,
Gordon B. Mills, Russell R. Broaddus,
John P. Lydon, Jeong Mook Lim, Ho-Geun Yoon,
and Jae-Wook Jeong
Precis: These findings provide a mechanistic rationale for
the evaluation of ERK1/2 inhibitors as a therapeutic
treatment in human endometrial cancer.
7383 Combined Genome and Transcriptome
Analysis of Single Disseminated Cancer Cells
from Bone Marrow of Prostate Cancer
Patients Reveals Unexpected Transcriptomes
Miodrag Guzvic, Bernhard Braun, Roman Ganzer,
Maximilian Burger, Michael Nerlich,
Sebastian Winkler, Melanie Werner-Klein,
Zbigniew T. Czy _z, Bernhard Polzer, and
Christoph A. Klein
Precis: Provocative indications of unexpected
transcriptome plasticity in disseminated cancer cells
challenge transcriptional criteria to identify these cells in
blood as early harbingers of metastatic disease.
7395 PELP1 Overexpression in the Mouse
Mammary Gland Results in the Development
of Hyperplasia and Carcinoma
Valerie Cortez, Cathy Samayoa, Andrea Zamora,
Lizatte Martinez, Rajeshwar R. Tekmal, and
Ratna K. Vadlamudi
Precis: A transcriptional coactivator of estrogen receptor
target genes acts as an oncogene in breast tumorigenesis,
with possible implications in understanding the etiology
and pathogenesis of estrogen receptor–positive breast
cancers.
7406 Differentiation and Loss of Malignant
Character of Spontaneous Pulmonary
Metastases in Patient-Derived Breast Cancer
Models
Jessica Bockhorn, Aleix Prat, Ya-Fang Chang,
Xia Liu, Simo Huang, Meng Shang,
Chika Nwachukwu, Maria J. Gomez-Vega,
J. Chuck Harrell, Olufunmilayo I. Olopade,
Charles M. Perou, and Huiping Liu
Precis:microRNAs contribute to the phenotypic regulation
of homed metastatic cells, loss of the mesenchymal state
and malignancy but gain of luminal epithelial
differentiation, compared with the parental tumor cells in
the primary site.
7418 Phosphoinositide Protein Kinase PDPK1 Is a
Crucial Cell Signaling Mediator in Multiple
Myeloma
Yoshiaki Chinen, Junya Kuroda, Yuji Shimura,
Hisao Nagoshi, Miki Kiyota,
Mio Yamamoto-Sugitani, Shinsuke Mizutani,
Natsumi Sakamoto, Masaki Ri, Eri Kawata,
Tsutomu Kobayashi, Yosuke Matsumoto,
Shigeo Horiike, Shinsuke Iida, and
Masafumi Taniwaki
Precis: These findings provide a preclinical rationale for
the development of inhibitors of a phosphotidylinositol
kinase as a generally effective treatment for deadly
multiple myelomas, regardless of their cytogenetic and
molecular profiles.
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7430 Oncogenic KRAS Confers Chemoresistance by
Upregulating NRF2
Shasha Tao, ShueWang, Seyed JavadMoghaddam,
Aikseng Ooi, Eli Chapman, Pak K. Wong, and
Donna D. Zhang
Precis: Although strategies to attack KRAS in tumors have
remained elusive, despite decades of research, this study
shows how it may be possible to ablate the most damaging
effect of KRAS mutations in conferring therapeutic
resistance, an exciting prospect with immediate clinical
implications.
PREVENTION AND EPIDEMIOLOGY
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Elissa C. Brown, Kara L. Cushing-Haugen,
Yingye Zheng, Ting-Yuan David Cheng,
Joshua W. Miller, Ralph Green, Dorothy S. Lane,
Shirley A.A. Beresford, and Marie A. Caudill
Precis: These results suggest that alterations in gut choline
metabolism may drive a higher risk of colon cancer,
possibly connected to changes in the gut microbiome.
THERAPEUTICS, TARGETS, AND CHEMICAL
BIOLOGY
7453 Endothelin A Receptor/b-Arrestin Signaling to
the Wnt Pathway Renders Ovarian Cancer
Cells Resistant to Chemotherapy
Laura Rosano`, Roberta Cianfrocca, Piera Tocci,
Francesca Spinella, Valeriana Di Castro,
Valentina Caprara, Elisa Semprucci,
Gabriella Ferrandina, Pier Giorgio Natali, and
Anna Bagnato
Precis: By linking endothelin signaling to chemoresistance
in ovarian cancer, this study suggests new strategies to
improve treatment outcomes in this disease setting.
7465 Quantitative In Vivo Immunohistochemistry of
Epidermal Growth Factor Receptor Using a
Receptor Concentration Imaging Approach
Kimberley S. Samkoe, Kenneth M. Tichauer,
Jason R. Gunn, Wendy A. Wells, Tayyaba Hasan,
and Brian W. Pogue
Precis: This study reports a robust in vivo measure of
receptor expression that is equivalent to ex vivo
immunostaining, with implications for use in noninvasive
monitoring of therapy or therapeutic guidance during
surgery.
7475 Syntheses and Discovery of a Novel Class of
Cinnamic Hydroxamates as Histone
Deacetylase Inhibitors by Multimodality
Molecular Imaging in Living Subjects
C.T. Chan, J. Qi, W. Smith, R. Paranol,
R. Mazitschek, N. West, R. Reeves, G. Chiosis,
S.L. Schreiber, J.E. Bradner, R. Paulmurugan, and
S.S. Gambhir
Precis: This study offers a preclinical proof of concept for
the selectivity and anticancer efficacy of a novel
hydroxamate-based class of small molecule HDAC
inhibitors.
7487 FL118 Induces p53-Dependent Senescence in
Colorectal Cancer Cells by Promoting
Degradation of MdmX
Xiang Ling, Chao Xu, Chuandong Fan, Kai Zhong,
Fengzhi Li, and Xinjiang Wang
Precis: The study defines a mechanism of action for an
experimental camptothecin-like agent, which exhibits a
superior preclinical antitumor activity related to its ability
to stimulate p53-dependent senescence.
7498 Mitochondrial MKP1 Is a Target for Therapy-
Resistant HER2-Positive Breast Cancer Cells
Demet Candas, Chung-Ling Lu, Ming Fan,
Frank Y.S. Chuang, Colleen Sweeney,
Alexander D. Borowsky, and Jian Jian Li
Precis: This study identifies a potential mechanism of
resistance in breast tumors and reveals the MAPK
phosphatase MKP1 as a therapeutic target to sensitize
resistant tumors and improve the efficacy of anticancer
therapy.
7510 Harnessing the Fcm Receptor for Potent and
Selective Cytotoxic Therapy of Chronic
Lymphocytic Leukemia
Berengere Vire, Martin Skarzynski,
Joshua D. Thomas, Christopher G. Nelson,
Alexandre David, Georg Aue, Terrence R. Burke Jr,
Christoph Rader, and Adrian Wiestner
Precis: These findings offer a basis to exploit an intrinsic
feature of chronic lymphocytic leukemia to improve the
selective delivery and efficacy of cytotoxic drugs to
eradicate this cancer.
7521 Serine Deprivation Enhances Antineoplastic
Activity of Biguanides
Simon-Pierre Gravel, Laura Hulea, Nader Toban,
Elena Birman, Marie-Jose Blouin,
Mahvash Zakikhani, Yunhua Zhao,
Ivan Topisirovic, Julie St-Pierre, andMichael Pollak
Precis: While more than 100 clinical trials are under way
to evaluate metformin and other biguanides in cancer
treatment, careful attention to nutritional and metabolic
factors that influence antineoplastic activity is needed to
optimize clinical trial designs.
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7534 Identification of ATR–Chk1 Pathway
Inhibitors That Selectively Target p53-
Deficient Cells without Directly Suppressing
ATR Catalytic Activity
Masaoki Kawasumi, James E. Bradner,
Nicola Tolliday, Renee Thibodeau, Heather Sloan,
Kay M. Brummond, and Paul Nghiem
Precis: These results highlight a set of new molecular
probes that act in a mechanistically novel manner to
inhibit the ATR-Chk1 checkpoint pathway and improve the
therapeutic responses produced by DNA damaging drugs.
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7546 Targeting the c-Met/FZD8 Signaling Axis
Eliminates Patient-Derived Cancer Stem–like
Cells in Head and Neck Squamous Carcinomas
Shuyang Sun, Suling Liu, Sheng Zhong Duan,
Lei Zhang, Henghua Zhou, Yongjie Hu,
Xianghui Zhou, Chaoji Shi, Rong Zhou, and
Zhiyuan Zhang
Precis: These results offer a preclinical proof of concept to
target the MET receptor kinase to improve the treatment of
head and neck squamous cancers, with immediate clinical
implications for repositioning MET inhibitors in human
trials.
7560 Downregulated miR329 and miR410 Promote
the Proliferation and Invasion of Oral
Squamous Cell Carcinoma by Targeting
Wnt-7b
Shine-Gwo Shiah, Jenn-RenHsiao,Wei-Min Chang,
Ya-Wen Chen, Ying-Tai Jin, Tung-Yiu Wong,
Jehn-ShyunHuang, Sen-Tien Tsai, Yuan-MingHsu,
Sung-Tau Chou, Yi-Chen Yen, Shih Sheng Jiang,
Yi-Shing Shieh, I-Shou Chang, Michael Hsiao, and
Jang-Yang Chang
Precis: These findings offer insight into the carcinogenic
properties of betel quid, a botanical that is sometimes
mixed with tobacco for use as an oral stimulant in the
Indian subcontinent and other regions of Asia.
7573 Targeting of miR34a–NOTCH1 Axis Reduced
Breast Cancer Stemness and Chemoresistance
Eun Young Park, EunSun Chang, Eun Ji Lee,
Hyun-Woo Lee, Hyeok-Gu Kang,
Kyung-Hee Chun, Yu Mi Woo, Hyun Kyung Kong,
Je Yeong Ko, Hiromu Suzuki, Erwei Song, and
Jong Hoon Park
Precis: Downregulation of a tumor suppressor miRNA
appears to be important in generating stem-like properties
and doxorubicin resistance in a well-established model of
estrogen-dependent breast cancer.
7583 Oncogene Pathway Activation in Mammary
Tumors Dictates FDG-PET Uptake
James V. Alvarez, George K. Belka, Tien-Chi Pan,
Chien-Chung Chen, Eric Blankemeyer, Abass Alavi,
Joel S. Karp, and Lewis A. Chodosh
Precis: PET scans are used commonly in the clinic to
image tumors on the basis of their elevated glucose uptake,
but the parameters underlying uptake of the imaging probe
have not been well understood, as explored by this study.
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ABOUT THE COVER
Myostatin gene inactivation drastically reduces the development of polyposis in ApcMin/þ mouse.
The ApcMin/þ mouse has a mutation in the adenomatous polyposis coli (Apc) tumor
suppressor gene, which is responsible for the development of colorectal cancer and cachexia.
Myostatin is a master negative regulator of skeletal muscle mass. It was found that inactivation
of the myostatin gene on the ApcMin/þ genetic background, a condition that completely
prevents cancer cachexia, strikingly reduced the number and size of intestinal polyps. For details
see article by Gallot and colleagues on page 7344.
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